活性胶原贴敷料研究报告

..................................................................................................31.1. 1.1.1. 1.1.2. 1.2. 1.2.1. 1.2.2. ............................................................................................132.1. 2.1.1. 2.1.2. 2.1.3. 2.1.4. ........................................................................................183.1. 3.1.1. 3.1.2. 3.2. 3.2.1. 3.3. Collagen30%ααααIIIIIIIIIIIIIIIIIIIII1.1.2.2828αICOL1A1[α1(I)]2α2(I)67nmCOL1A2[α1(I)]3IICOL2A1[α1(II)]3IIICOL3A1[α1(III)]3αVCOL5A1[α1(V)]2α2(V)9nmCOL5A2[α1(V)α2(V)α3(V)]COL5A3[α1(V)]3XICOL11A1[α1(XI)α2(XI)α3(XI)]VCOL11A2XXIVCOL24A1[α1(XXIV)]3XXVIICOL27A1[α1(XXVII)]3IXCOL9A1[a1(IX)a2(IX)a3(IX)]IICOL9A2COL9A3XIICOL12A1[a1(XII)]3IXIVCOL14A1[a1(XIV)]3I IIXVICOL16A1a1(XVI)-1 DIIαFACITXIXCOL19A1a1(XIX)N-[a1(XIX)]2[a1(XIX)]3[a1(XIX)]4[a1(XIX)]5[a1(XIX)]6XXCOL20A1a1(XX)XXIICOL22A1a1(XXII)-IVCOL4A1[a1(IV)]2a2(IV)COL4A2[a1(IV)]2a3(IV)COL4A3[a1(IV)]2a4(IV)COL4A4[a1(IV)]2a5(IV)COL4A5[a1(IV)]2a6(IV)VIICOL7A1[a1(VII)]3XVIIICOL18A1a1(XVIII)αMACITsXIIICOL13A1a1(XIII)XXIIICOL23A1a1(XXIII)XXVCOL25A1a1(XXV)RXXVICOL26A1a1(XXVI)XVIIICOL18A1a1(XVIII)XVCOL15A1a1(XV)XXVIIICOL28A1a1(XXVIII)1.2.1.Collagen-relatedPeptideCRP••••••••1.2.2.19811981ZydermⅠII200920091122Ca(OH)2 NaOH1.2.3.11,,2233,,44,,,,,,,55,,,,66,,,,( SAL=10-6),,2.1.1.2.1.2.202411720241172.1.3.“”“”2.1.4.202220221136416 1136202631.9%20263.1.1. //02024 4002024112024113%7%5%33%20%3%7%5%33%20%32%凝胶冻干其他20241140 /20241140 /2024112024115%三类医疗器械二类医疗器械3.1.2.2024112024112015314100520163141290202031400402021314033420223140734202331406152023314123220233141576202331419572024314155020243141788◼2004 2004 26403292004 2005 2009 92012 A2013 32014 2◼GB18280/ISO1113720162015A( )602016(I◼ 2022Q320242022Q3210021006006002024Q32024Q31>6002A~1203B~90◼ 2022Q320242022Q3332022202320241~174,300~260,700~212,2002A~112,500~162,000~160,2003B~39,600~49,050~50,4002022202320241~134,900~177,400~138,4002A~48,000~69,000~71,0003B~16,000~24,000~25,000◼ 2022Q320242022Q3332022202320241~683,700~1,173,400~1,129,9002A~250,000~360,000~356,0003B~88,000~109,000~112,000◼ 2022Q320242022Q310001000“”2002“”2002“1.“””2.2024103221108632.2024103221108633.“”“”“” ““” “”* “”“” *HenkelW,GlanvilleRW.CovalentcrosslinkingbetweenmoleculesoftypeIandtypeIIIcollagen:TheinvolvementoftheN-terminal,nonhelicalregionsoftheal(I)andal(III)chainsintheformationofintermolecularcrosslinks.EurJBiochem,1982,122:205-213.XiaL,ChenY,MenF,ZhangY,ChenW,ZhengX,WangH,ZhangJ,LiuH,ZhaoB.Comparativestudyonphysicalpropertiesofdifferenttissue-derivedcollagenbiomaterials.MaterialsScience,2017,7(4):431-439.Gromkowska-Kępka,K.J.;Puścion-Jakubik,A.;Markiewicz-Żukowska,R.;Socha,K.Theimpactofultravioletradiationonskinphotoaging—reviewofinvitrostudies.J.Cosmet.Dermatol.2021,20,3427–3431.doi:10.1111/jocd.14033Fidler,A.L.;Boudko,S.P.;Rokas,A.;Hudson,B.G.Thetriplehelixofcollagens–anancientproteinstructurethatenabledanimalmulticellularityandtissueevolution.J.CellSci.2018,131,jcs203950.Frank,M.,Albuisson,J.,Ranque,B.,Golmard,L.,Mazzella,J.,Bal-Theoleyre,L.,Jeunemaitre,X.(2015).ThetypeofvariantsattheCOL3A1geneassociateswiththephenotypeandseverityofvascularEhlers–Danlossyndrome.EuropeanJournalofHumanGenetics,23,1657–1664.Liu,X.,Wu,H.,Byrne,M.,Krane,S.,&Jaenisch,R.(1997).TypeIIIcollageniscrucialforcollagenIfibrillogenesisandfornormalcardiovasculardevelopment.ProceedingsoftheNationalAcademyofSciences,94(5),1852–1856.Kuivaniemi,H.,&Tromp,G.(2019).TypeIIIcollagen(COL3A1):Geneandproteinstructure,tissuedistribution,andassociateddiseases.Gene,707,151–171.Wang,C.,Brisson,B.K.,Terajima,M.,Li,Q.,Hoxha,K.,Han,B.,Goldberg,A.M.,Liu,X.S.,Marcolongo,M.S.,Enomoto-Iwamoto,M.,Yamauchi,M.,Volk,S.W.,Han,L.(2020).TypeIIICollagenisaKeyRegulatoroftheCollagenFibrillarStructureandBiomechanicsofArticularCartilageandMeniscus.MatrixBiology,85-86,47–67.Singh,D.,Rai,V.,Agrawal,D.K.(2023).RegulationofCollagenIandCollagenIIIinTissueInjuryandRegeneration.CardiolCardiovascMed.,7(1),5–16.Rodrigues,M.,Kosaric,N.,B